8-K: Rapport Therapeutics Q3: RAP-219 Shines, Cash Strong

Rapport Therapeutics announced positive Phase 2a results for RAP-219 in focal onset seizures, bolstered its balance sheet with a $269.4 million public offering, and reported Q3 2025 financials.

Summary

• Positive topline results were announced from the Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures (FOS).
• RAP-219 achieved a 77.8% median reduction in clinical seizures and 24% of patients achieved seizure freedom for the 8-week treatment period in the FOS trial.
• The Phase 2 trial of RAP-219 in bipolar mania is enrolling patients, with topline results expected in the first half of 2027.
• A public offering was completed in September, generating approximately $269.4 million in net proceeds.
• The company ended the third quarter of 2025 with $513.0 million in cash, cash equivalents, and short-term investments.
• The current cash position is expected to fund operations into the second half of 2029.
• Net loss for the third quarter of 2025 was $26.9 million, compared to $17.5 million for the prior year period.
• Research and Development (R&D) expense increased to $22.3 million for Q3 2025 from $15.5 million in Q3 2024.
• General and Administrative (G&A) expense increased to $7.7 million for Q3 2025 from $6.1 million in Q3 2024.
• The Investigational New Drug (IND) for a Phase 2 trial of RAP-219 in Diabetic Peripheral Neuropathic Pain (DPNP) is currently on clinical hold with the FDA.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical trial results for RAP-219 in focal onset seizures, demonstrating significant efficacy and a favorable tolerability profile. The successful public offering substantially bolstered the company's financial position, extending its cash runway for several years. While net loss and expenses increased, this is expected for a clinical-stage biotech advancing its pipeline. The clinical hold on the DPNP program is a minor setback but does not overshadow the primary positive developments.

Positives

• Positive Phase 2a topline results for RAP-219 in drug-resistant focal onset seizures, meeting primary long episode (LE) endpoints with high statistical significance.
• 85.2% of FOS patients achieved 30% reduction in LEs compared with baseline (p<0.0001).
• 77.8% median reduction in clinical seizures (p=0.01) and 72% of patients achieved 50% reduction in clinical seizures (p<0.0001) in the FOS trial.
• 24% of FOS patients achieved seizure freedom for the 8-week treatment period (p<0.0001).
• RAP-219 was generally well-tolerated in the FOS trial, with the majority of treatment-emergent adverse events (TEAEs) being mild and a 10% discontinuation rate attributed to TEAEs.
• Successful completion of an underwritten public offering, raising approximately $269.4 million in net proceeds, significantly strengthening the balance sheet.
• Strong cash position of $513.0 million in cash, cash equivalents, and short-term investments as of September 30, 2025.
• Extended cash runway into the second half of 2029, providing substantial financial stability for ongoing and planned clinical development.
• Plans to initiate two Phase 3 pivotal trials of RAP-219 in FOS in the third quarter of 2026.
• Development of a Long-acting Injectable (LAI) formulation for RAP-219 is underway, with potential to transform the treatment landscape, expand commercial opportunity, and extend intellectual property runway.

Negatives

• Net loss increased to $26.9 million for the third quarter of 2025, compared to $17.5 million for the prior year period.
• Research and Development (R&D) expense increased to $22.3 million for the third quarter of 2025, compared to $15.5 million for the prior year period.
• General and Administrative (G&A) expense increased to $7.7 million for the third quarter of 2025, compared to $6.1 million for the prior year period.
• The IND for a Phase 2 proof-of-concept trial of RAP-219 in Diabetic Peripheral Neuropathic Pain (DPNP) is currently on clinical hold with the FDA.

Risks

• Risks relating to the company's research and development activities.
• Ability to execute on strategy, including obtaining requisite regulatory approvals on the expected timeline, if at all.
• Uncertainties relating to preclinical and clinical development activities.
• Dependence on third parties to conduct clinical trials, manufacture product candidates, and develop and commercialize product candidates, if approved.
• Ability to attract, integrate, and retain key personnel.
• Risks related to the company's financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved.
• Risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities.
• Risks related to establishing and maintaining intellectual property protections.
• Risks related to the competitive landscape for the company's product candidates.

Future Outlook

Rapport Therapeutics plans to hold an end-of-Phase 2 meeting with the FDA by the end of 2025 and initiate two Phase 3 pivotal trials for RAP-219 in focal onset seizures in the third quarter of 2026. Topline results for the Phase 2 bipolar mania trial are anticipated in the first half of 2027, and initial pharmacokinetics results for a long-acting injectable formulation of RAP-219 are expected in 2027. The company expects its current cash position to fund operations into the second half of 2029.

Management Comments

• "The positive Phase 2a results for RAP-219 announced in September underscore both the strength of our precision neuroscience platform and the compounds differentiated clinical potential." Abraham N. Ceesay, chief executive officer of Rapport.
• "Achieving a nearly 78% median reduction in clinical seizures and seizure freedom in nearly one in four patients positions RAP-219 with a potential best-in-class profile for the treatment of drug-resistant focal onset seizures." Abraham N. Ceesay, chief executive officer of Rapport.
• "With a strengthened balance sheet following our recent public offering, we are in a strong financial position to execute our Phase 3 trials in focal onset seizures and continue advancing our bipolar Phase 2 trial toward topline results expected in the first half of 2027." Abraham N. Ceesay, chief executive officer of Rapport.
• "We remain committed to disciplined execution and delivering sustained value for both patients and shareholders." Abraham N. Ceesay, chief executive officer of Rapport.

Industry Context

Rapport Therapeutics is developing RAP-219 as a potential first-in-class TARP8-specific AMPA receptor negative allosteric modulator (NAM). This precision approach, targeting TARP8 expression in discrete brain regions like the hippocampus and neocortex where focal seizures often originate, aims to provide a differentiated profile compared to traditional neuroscience medications by minimizing adverse events associated with hindbrain activity. This strategy positions RAP-219 to potentially offer a best-in-class profile for drug-resistant focal onset seizures and address other neurological disorders like bipolar disorder and neuropathic pain, where AMPA biology plays a role.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, strengthened balance sheet, extended cash runway, and advancement towards Phase 3 trials, potentially increasing long-term value.
• Patients (Focal Onset Seizures): Highly positive, as RAP-219 shows potential for a best-in-class treatment with significant seizure reduction and freedom, offering hope for drug-resistant cases.
• Patients (Bipolar Mania): Continued progress with Phase 2 enrollment, maintaining hope for a new treatment option.
• Patients (DPNP): Uncertainty due to clinical hold, delaying potential treatment options.
• Employees: Positive outlook due to strong financial position and pipeline advancement, ensuring job security and continued research opportunities.
• Regulatory Authorities (FDA): Engagement with an end-of-Phase 2 meeting planned, indicating progression through regulatory pathways.

Next Steps

• Present further efficacy analyses for FOS later in 2025.
• Hold an end-of-Phase 2 meeting with the FDA by the end of 2025.
• Allow patients from the Phase 2a FOS trial to resume RAP-219 in an open-label, long-term safety trial by the end of 2025.
• Present additional FOS data, including 8-week follow-up, in 2026.
• Determine next steps for the DPNP program in the first quarter of 2026.
• Initiate two Phase 3 pivotal trials of RAP-219 in FOS in the third quarter of 2026.
• Expect initial pharmacokinetics results for the LAI formulation of RAP-219 in 2027.
• Expect topline results for the Phase 2 trial of RAP-219 in bipolar mania in the first half of 2027.

Key Dates

Recommendation

The positive Phase 2a results for RAP-219 in focal onset seizures are highly compelling, demonstrating significant efficacy (77.8% median seizure reduction, 24% seizure freedom) and a favorable safety profile, positioning it as a potential best-in-class therapy. The successful $269.4 million public offering has substantially de-risked the company financially, extending its cash runway into the second half of 2029, which is critical for a clinical-stage biotech. The clear path to Phase 3 trials in FOS and ongoing development in bipolar mania and an LAI formulation indicate strong pipeline progression and future commercial potential. While the DPNP program faces a clinical hold, this is a minor setback compared to the significant positive developments in the lead program. The overall outlook is very strong, warranting a 'strong buy' recommendation for investors seeking exposure to innovative neuroscience therapeutics.

Keywords

Rapport Therapeutics, RAP-219, Focal Onset Seizures, Bipolar Mania, Diabetic Peripheral Neuropathic Pain, Biotechnology, Clinical Trials, Phase 2a, Phase 3, Financial Results, Neuroscience, Precision Medicine, TARP8, AMPA receptor, Public Offering, Cash Runway